113 |
Frailty Assessment and How to Define Futile TAVR |
Alan C. Yeung |
Aug. 12. 16 |
112 |
Durability of THV and Management of Failed THV |
John Graydon Webb |
Aug. 12. 16 |
111 |
TAVR in Lower Risk |
Eberhard Grube |
Aug. 12. 16 |
110 |
New View on Pathogenesis of Cardiovascular Calcification |
Elena Aikawa |
Aug. 12. 16 |
109 |
AP TAVR Registry |
Jung-Min Ahn |
Aug. 12. 16 |
108 |
Current Status of TAVI in Japan |
Kentaro Hayashida |
Aug. 12. 16 |
107 |
Edwards CENTERA Self-Expanding THV System - Initial Experience |
Darren L. Walters |
Aug. 12. 16 |
106 |
VENUS A China Trial |
Yongjian Wu |
Aug. 12. 16 |
105 |
Lotus |
Hyo-Soo Kim |
Aug. 12. 16 |
104 |
Evolut R |
Eberhard Grube |
Aug. 12. 16 |